- Recruiting
NCT02465060: Phase 2: Targeted Therapy Directed by Genetic Testing in Treating Patients With RRMM
Updated: Sep 24, 2022
NCT02465060: phase 2: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
Sponsor
National Cancer Institute (NCI)
ECOG-ACRIN Cancer Research Group
ClinicalTrials.gov Identifier: NCT02465060
Official Title: Molecular Analysis for Therapy Choice (MATCH)
First Posted: June 8, 2015
Click here for details on ClinicalTrials.gov
EAY131 / NCI MATCH Home Page - ECOG-ACRIN Cancer Research Group
Drug: Adavosertib
Definition of adavosertib - NCI Drug Dictionary - NCI (cancer.gov)
Drug: Afatinib
Drug: Afatinib Dimaleate
Definition of afatinib dimaleate - NCI Drug Dictionary - NCI (cancer.gov)
Drug: Binimetinib
Definition of binimetinib - NCI Drug Dictionary - NCI (cancer.gov)
Drug: Capivasertib
Definition of capivasertib - NCI Drug Dictionary - NCI (cancer.gov)
Drug: Copanlisib
Definition of copanlisib hydrochloride - NCI Drug Dictionary - NCI (cancer.gov)
Drug: Copanlisib Hydrochloride
Definition of copanlisib hydrochloride - NCI Drug Dictionary - NCI (cancer.gov)
Drug: Crizotinib
Definition of crizotinib - NCI Drug Dictionary - NCI (cancer.gov)
Other: Cytology Specimen Collection Procedure
Drug: Dabrafenib
Definition of dabrafenib mesylate - NCI Drug Dictionary - NCI (cancer.gov)
Drug: Dabrafenib Mesylate
Definition of dabrafenib mesylate - NCI Drug Dictionary - NCI (cancer.gov)
Drug: Dasatinib
Definition of dasatinib - NCI Drug Dictionary - NCI (cancer.gov)
Drug: Defactinib
Definition of defactinib - NCI Drug Dictionary - NCI (cancer.gov)
Drug: Defactinib Hydrochloride
Drug: Erdafitinib
Definition of erdafitinib - NCI Drug Dictionary - NCI (cancer.gov)
Drug: FGFR Inhibitor AZD4547
Definition of FGFR inhibitor AZD4547 - NCI Drug Dictionary - NCI (cancer.gov)
Drug: Ipatasertib
Definition of ipatasertib - NCI Drug Dictionary - NCI (cancer.gov)
Other: Laboratory Biomarker Analysis
Drug: Larotrectinib
Drug: Larotrectinib Sulfate
Definition of larotrectinib sulfate - NCI Drug Dictionary - NCI (cancer.gov)
Biological: Nivolumab
Definition of nivolumab - NCI Drug Dictionary - NCI (cancer.gov)
Drug: Osimertinib
Definition of osimertinib mesylate - NCI Drug Dictionary - NCI (cancer.gov)
Drug: Palbociclib
Definition of palbociclib - NCI Drug Dictionary - NCI (cancer.gov)
Biological: Pertuzumab
Definition of pertuzumab - NCI Drug Dictionary - NCI (cancer.gov)
Drug: PI3K-beta Inhibitor GSK2636771
Definition of PI3K-beta inhibitor GSK2636771 - NCI Drug Dictionary - NCI (cancer.gov)
Biological: Relatlimab
Definition of relatlimab - NCI Drug Dictionary - NCI (cancer.gov)
Drug: Sapanisertib
Definition of sapanisertib - NCI Drug Dictionary - NCI (cancer.gov)
Drug: Sunitinib Malate
Definition of sunitinib malate - NCI Drug Dictionary - NCI (cancer.gov)
Drug: Taselisib
Definition of taselisib - NCI Drug Dictionary - NCI (cancer.gov)
Drug: Trametinib
Biological: Trastuzumab
Definition of trastuzumab - NCI Drug Dictionary - NCI (cancer.gov)
Biological: Trastuzumab Emtansine
Definition of ado trastuzumab emtansine - NCI Drug Dictionary - NCI (cancer.gov)
Drug: Ulixertinib
Definition of ulixertinib - NCI Drug Dictionary - NCI (cancer.gov)
Drug: Vismodegib
Definition of vismodegib - NCI Drug Dictionary - NCI (cancer.gov)
Locations
United States, Alabama
United States, Alaska
United States, Arizona
United States, Arkansas
United States, California
United States, Colorado
United States, Connecticut
United States, Delaware
United States, District of Columbia
United States, Florida
United States, Georgia
United States, Hawaii
United States, Idaho
United States, Illinois
United States, Indiana
United States, Iowa
United States, Kansas
United States, Kentucky
United States, Louisiana
United States, Maine
United States, Maryland
United States, Massachusetts
United States, Michigan
United States, Minnesota
United States, Mississippi
United States, Missouri
United States, Montana
United States, Nebraska
United States, Nevada
United States, New Jersey
United States, New Mexico
United States, New York
United States, North Carolina
United States, North Dakota
United States, Ohio
United States, Oklahoma
United States, Oregon
United States, Pennsylvania
United States, Rhode Island
United States, South Carolina
United States, South Dakota
United States, Tennessee
United States, Texas
United States, Utah
United States, Vermont
United States, Virginia
United States, Washington
United States, West Virginia
United States, Wisconsin
United States, Wyoming
Guam
Puerto Rico
Other ECOG Trials
NCT04566328: Phase 3 - EAA181 / EQUATE - Testing the Use of Combination Therapy in NDMM
NCT03937635: Phase 3 - EAA173 / DETER-SMM - Lenalidomide, Dex +/- Daratumumab in High-Risk Smoldering Myeloma
NCT03941860: Phase 3 - EAA171 / OPTIMUM - Addition of Ixazomib to Lenalidomide in Patients With Residual Myeloma
NCT02465060: Phase 2 - EAY131 / NCI-MATCH - Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)